P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES

Bibliographic Details
Main Authors:	M. Gertz, A. Cohen, R. Comenzo, E. Kastritis, H. Landau, E. Libby, M. Liedtke, V. Sanchorawala, S. Schönland, A. Wechalekar, Y. Ando, Y. Koh, J. Zonder, G. Palladini, C. Nie, C. Karp, Y. Jin, A. Conrad, G. Kinney, G. Merlini
Format:	Article
Language:	English
Published:	Wiley 2023-05-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000936352.84768.4d

Internet